Special Drug Use Investigation for PAXIL (Paroxetine) Social Anxiety Disorder (Long-term)
Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Social Phobia
Intervention: Paroxetine (Drug)
Phase: N/A
Status: Completed
Sponsored by: GlaxoSmithKline Official(s) and/or principal investigator(s): GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline
Summary
The study is designed to evaluate the safety and efficacy of paroxetine on the long-term use
in Japanese Social Anxiety Disorder (SAD) subjects.
Clinical Details
Official title: Special Drug Use Investigation for PAXIL (Paroxetine) Social Anxiety Disorder (Long-term)
Study design: N/A
Primary outcome: The number of adverse events in Japanese subjects with social anxiety disorder treated with paroxetine tablets
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Subjects who are diagnosed as having SAD
- Subjects who are expected to use paroxetine tablets for the first time
Exclusion Criteria:
- Subjects taking pimozide
- Subjects taking monoamine oxidase (MAO) inhibitor or within two weeks after
discontinuation of MAO inhibitor
- Subjects with hypersensitivity to paroxetine
Locations and Contacts
Additional Information
Starting date: January 2010
Last updated: June 30, 2014
|